rivastigmine clinical trials

Introduction

Reviewer's conclusions:

• rivastigmine appears to be beneficial for people with mild to moderate Alzheimer's disease
• in comparison to placebo, 6-12 mg QD improved
  • cognitive function
  • activities of daily living (ADL)
  • severity of dementia
• adverse effects consistent with cholinergic agonist activity
• economic impact not investigated

Methods

• 7 controlled trials involving 3370 individuals included
• 2.1 point improvement in cognitive function on ADAS-Cog score relative to placebo
• 2.2 point improvement in ADL determined by progressive deterioration scale

Additional terms

• activities of daily living (ADL)
• Alzheimer's disease assessment scale (ADAS)
• cognition (intelligence)
• rivastigmine (Exelon)